Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06238661 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prostate Cancer Screening: a Pilot Study

Study acronym: ProScreenMRI
StatusEnrolling by Invitation
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 5, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Primary completion date: Jan 1, 2026 to Jun 30, 2026
    • Start date changed from estimate of Jan 1, 2025 to Feb 17, 2025
    • Site contact updated
    v4
  3. Primary completion date: Dec 1, 2024 to Jan 1, 2026v3 Show 4 more changesShow less
    • Start date: May 1, 2024 to Jan 1, 2025
    • Study completion date: Jul 1, 2025 to Jun 30, 2026
    • Site details revised
    • Collaborators: 2 to 3
  4. Start date: Mar 1, 2024 to May 1, 2024v2 Show 4 more changesShow less
    • Trial status: Enrolling by Invitation to Not Yet Recruiting
    • Secondary endpoints revised (2)
    • Study site revised
    • Study title shortened, about 7 words
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prostate Cancer (PCa) is the second most frequently diagnosed tumour and the third most lethal among men in Europe. The lack of precise tools and examinations to precisely diagnose PCa has caused overtreatment of indolent and low-aggressive PCa, while in some other cases, with aggressive disease, diagnosis and treatment are dangerously delayed because cancer could be potentially missed. The present trial aims to study a new pathway to early diagnose PCa with Magnetic Resonance Imaging (MRI) to identify men who will not need treatment and those who will benefit from radical treatment, thus improving disease control and quality of life.
Trial Details
NCT Number NCT06238661
Lead Sponsor Fondazione del Piemonte per l'Oncologia
Collaborators: San Luigi Gonzaga Hospital, Epidemiology and Screening Unit - CPO, Turin, Italy, ASL TO5
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 4,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov